Prospect of acromegaly therapy: molecular mechanism of clinical drugs octreotide and paltusotine
Open Access
- 21 February 2023
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-14
Abstract
Somatostatin receptor 2 (SSTR2) is highly expressed in neuroendocrine tumors and represents as a therapeutic target. Several peptide analogs mimicking the endogenous ligand somatostatin are available for clinical use, but poor therapeutic effects occur in a subset of patients, which may be correlated with subtype selectivity or cell surface expression. Here, we clarify the signal bias profiles of the first-generation peptide drug octreotide and a new-generation small molecule paltusotine by evaluating their pharmacological characteristics. We then perform cryo-electron microscopy analysis of SSTR2-Gi complexes to determine how the drugs activate SSTR2 in a selective manner. In this work, we decipher the mechanism of ligand recognition, subtype selectivity and signal bias property of SSTR2 sensing octreotide and paltusotine, which may aid in designing therapeutic drugs with specific pharmacological profiles against neuroendocrine tumors.Keywords
This publication has 59 references indexed in Scilit:
- Peptide Receptor Targeting in Cancer: The Somatostatin ParadigmInternational Journal of Peptides, 2013
- Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experiencePituitary, 2012
- Structural Determinants of Agonist-Selective Signaling at the sst2A Somatostatin ReceptorMolecular Endocrinology, 2011
- PHENIX: a comprehensive Python-based system for macromolecular structure solutionActa Crystallographica Section D Structural Biology, 2010
- MolProbity: all-atom structure validation for macromolecular crystallographyActa Crystallographica Section D Structural Biology, 2009
- Acromegaly pathogenesis and treatmentJournal of Clinical Investigation, 2009
- Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatmentPituitary, 2009
- The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenomaClinical Endocrinology, 2007
- Coot: model-building tools for molecular graphicsActa Crystallographica Section D Structural Biology, 2004
- UCSF Chimera—A visualization system for exploratory research and analysisJournal of Computational Chemistry, 2004